| abstract |
Use of a sustained release opioid oral dosage form comprising a mixture of an opioid agonist selected from the group consisting of oxycodone, hydrocodone, hydromorphone, morphine, methadone, oxymorphone, fentanyl and sufentanil in free base form or a pharmaceutically acceptable salt and opioid antagonist group selected from , nalmefene and naloxone in the form of a free base or a pharmaceutically acceptable salt, for the manufacture of a medicament for the treatment of patients with Restless Legs Syndrome (RLS). The application contains 10 further dependent claims. |